Analyst upgrades: AAPL, UBS, AZN and KLAC
Posted Apr 7th 2008 11:08AM by Eric Buscemi
Filed under: Analyst reports, Analyst upgrades and downgrades, Apple Inc (AAPL), Anglo American (AAUKY)
MOST NOTEWORTHY: Apple, AstraZeneca and KLA-Tencor were today's noteworthy upgrades:
- Thomas Weisel upgraded Apple (NASDAQ: AAPL) to Overweight from Market Weight, citing a re-set in FY08 expectations and expected growth from Mac market share gains, accelerating iPhone revenue growth and increased iPhone ASPs.
- WestLB upgraded shares of AstraZeneca (NYSE: AZN) to Add from Hold as they believe the company's growth in core franchises are being overlooked.
- Citigroup upgraded KLA-Tencor (NASDAQ: KLAC) to Buy from Hold , as they believe several near-term catalysts are likely to develop against an increasingly favorable cyclical backdrop. They think KLAC's near-term business is better than most think and maintain a $56 target on the stock.
OTHER UPGRADES:
- Goldman upgraded Anglo American (NASDAQ: AAUK) to Buy from Neutral and added shares to the Conviction Buy List.
- UBS (NYSE: UBS) was upgraded to Buy from Neutral at Merrill and added to the Europe 1 List.
- Jefferies raised comScore (NASDAQ: SCOR) to Buy from Hold.
Tags: aapl, aauk, analyst, anglo american, AngloAmerican, apple, astrazeneca, azn, comscore, inthenews, kla-tencor, klac, scor, ubs, upgrade